NCT03124082

Brief Summary

Opioids have been used for analgesia since many years, but despite potent analgesia they are also associated to side effects, including opioid induced Hyperalgesia (OIH). OIH in the surgical setting is debated, and may predispose patients to higher analgesic consumption in the preoperative period, and peripheral and central sensitization. The aim of the study is to compare remifentanil-based vs non opioid analgesia (clonidine, lidocaine, ketamine) for intraoperative management of patients undergoing laparoscopic left hemicolectomy, with the hypothesis that non- opiod treated patients will have lower morphine consumption in the first 24 hours after surgery. Peripheral and central hyperalgesia will be tested with Von Frey hairs and pin-prick to evaluate acute CNS (Central Nervous System) sensitization after surgery. Acute and persistent (1 and 3 months) pain will be registered, together with any side effect and parameters of surgical rehabilitation.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
64

participants targeted

Target at P25-P50 for phase_4 postoperative-pain

Timeline
Completed

Started Jan 2017

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 4, 2017

Completed
18 days until next milestone

First Submitted

Initial submission to the registry

January 22, 2017

Completed
3 months until next milestone

First Posted

Study publicly available on registry

April 21, 2017

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2017

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2018

Completed
Last Updated

April 21, 2017

Status Verified

April 1, 2017

Enrollment Period

12 months

First QC Date

January 22, 2017

Last Update Submit

April 18, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • analgesic consumption

    morphine mg by PCA (Patient Controlled Analgesia)

    24 HOURS

Secondary Outcomes (4)

  • side effects

    4 days after surgery

  • Pain Score on the Visual Analog Scale

    3 months

  • peripheral sensitization

    24 hours

  • central sensitization

    24 hours

Study Arms (2)

opioid

ACTIVE COMPARATOR

remifentanil 0,15-0,25 mcg/kg/h

Drug: Remifentanil

opioid free

EXPERIMENTAL

ketamine bolus 0,5 mg/kg + infusion 0,25 mg/kg/h lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h clonidine 4 mcg/kg

Drug: KetamineDrug: LidocaineDrug: Clonidine

Interventions

continuous infusion intraop

opioid

bolus 0,5 mg/kg + infusion 0,25 mg/kg/h

opioid free

lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h

opioid free

clonidine 4 mcg/kg

opioid free

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • left hemicolectomy
  • signed informed consent
  • \>18 ys

You may not qualify if:

  • \>90 ys \<18 ys
  • no consent
  • pregnancy
  • psychiatric disease
  • cardiac failure, aortic or mitral valve severe stenosis
  • kidney or hepatic failure
  • atrio-ventricular type II block
  • immunodepression
  • emergency surgery
  • ICU admittance
  • drug or alcohol abuse
  • chronic pain

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital

Parma, Parma, 43100, Italy

RECRUITING

MeSH Terms

Conditions

Pain, Postoperative

Interventions

RemifentanilKetamineLidocaineClonidine

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

PropionatesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsAcetanilidesAnilidesAmidesAniline CompoundsAminesImidazolinesImidazolesAzoles

Central Study Contacts

Bugada Dario, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: randomized double blind trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, Assistant Professor

Study Record Dates

First Submitted

January 22, 2017

First Posted

April 21, 2017

Study Start

January 4, 2017

Primary Completion

December 31, 2017

Study Completion

March 31, 2018

Last Updated

April 21, 2017

Record last verified: 2017-04

Data Sharing

IPD Sharing
Will not share

Locations